Pfizer Scientist Highlights AI in Platform Formulations
Stephanie Johnson outlined how platform formulations and AI tools streamline early drug development at a New Orleans conference.
Updated on Oct. 27, 2026 in Artificial Intelligence
Live Poll
Do you trust artificial intelligence to make accurate decisions in professional or technical fields?
Pfizer principal scientist Stephanie Johnson presented new insights on platform formulations at the AAPS PharmSci 360 conference in New Orleans. The presentation focused on leveraging AI tools to accelerate early-stage drug development processes.
Why it matters
Platform formulations allow research teams to save significant time by narrowing the defined space before committing to a specific drug product. Using AI in this capacity helps researchers predict which molecules are best suited for these platforms.
Pfizer research conducted over the last 5 years emphasizes shifting risk downstream while converting developmental risk into manageable debt. Successful integration relies on linking molecular and physical properties to robust stability datasets.
The players
Stephanie Johnson
She serves as a principal scientist of formulation development at Pfizer and presented at the AAPS PharmSci 360 conference.
Pfizer
A multinational pharmaceutical and biotechnology corporation that conducts extensive research into drug development and formulation technologies.
The details
By utilizing platform formulations, teams can focus time and materials on a narrower defined space during initial stages. The reliability of these AI-driven models depends entirely on the quality of the training datasets used to link molecular performance to actual stability data.
Timeline
The AAPS PharmSci 360 conference took place in New Orleans from October 25-28, 2026.
Pfizer has focused on early-stage drug development research for the past 5 years.
The Tech Race
The transition toward AI-driven drug development mirrors a broader shift within the pharmaceutical industry to replace manual trial-and-error processes with predictive modeling. These advancements are rapidly replacing traditional legacy development systems that previously required longer timelines.
While these technologies operate behind the scenes, they aim to speed up the delivery of new medications to the public. For researchers and developers, these methods represent a major workflow improvement by automating complex stability predictions.
The takeaway
Adopting AI in formulation development turns developmental risk into a manageable technical process. Researchers should prioritize high-quality training data to ensure their predictive models remain accurate and reliable.
Further reading
Learn more about emerging trends in Artificial Intelligence applications within the pharmaceutical industry.
Source note: This article includes information reported by BioPharm International.
Live Poll
Do you trust artificial intelligence to make accurate decisions in professional or technical fields?
